Overview

• The University of Texas Health Science Center at San Antonio conducted a preclinical study using a mouse model to test direct TMJ botulinum toxin injections for temporomandibular disorder
• Joint-targeted delivery avoids the muscle weakening risks associated with conventional botox therapies
• This approach departs from traditional anti-inflammatory and muscle-focused treatments for jaw disorders
• Molecular studies revealed that treated mice had lower pain-promoting protein levels and reduced neural hypersensitivity
• The research team aims to determine sex-specific effects and advance toward initial human trials